TickerTalks
Browse all tickers →
TickerTalks›$ORKA
ORORKA

Oruka Therapeutics, Inc.

$ORKA·$6.0B·Biotechnology·Healthcare
$92.62+1.6%YTD+223.8%1Y+495.2%
Mentions · last 7 days
2026-08-22: 1 posts2026-08-23: 7 posts65-21%
Price updated 7h ago·X counts updated 8d ago
ORORKA
$ORKAOruka Therapeutics, Inc.
$92.62+1.62%65 posts-21%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ORKA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Oruka up 497% T12M — orka-001 Phase 1 28-week data due late Q3, $1.1B cash, and a $500M ATM just filed.

Oruka Therapeutics is a clinical-stage biotech developing next-generation monoclonal antibody therapies for psoriasis (PsO) and other inflammatory conditions — the equity is up an extraordinary 497% T12M as the pipeline positioning combined with strong balance-sheet flexibility.

  • Revenue is functionally zero: quarterly EPS ran -$0.45 to -$0.69, with FY26 consensus supporting continued negative EPS — the equity trades entirely on trial-readout catalysts and the potential for a large pharma buyout given the differentiated PsO positioning.
  • The specific catalyst is imminent: orka-001 Phase 1 28-week data due late Q3 2026 (with 52-week data in December), plus orka-001 Phase 2b fully enrolled early with 187 subjects — that's a defined dated readout window into a very-well-financed clinical program.
  • The balance-sheet cushion is real: $1.1B in cash (fully funded through BLA filing) plus the Aug 28 filing of a $500M ATM program means Oruka has essentially the entire operating runway funded — the FMC (fair market cap) at $100/share implies a ~$7.7B market cap where the current $91.14 tape sits close.
  • Institutional flow is genuinely constructive: BlackRock purchasing 4,990,181 shares (Aug 25) plus a new Chief Commercial Officer (Todd Edwards appointed Aug 24) with a $2M grant — the ownership base is rebuilding into the specific catalyst window ahead.

The path if the readout is positive is late-Q3 orka-001 Phase 1 28-week data showing efficacy plus continued Phase 2b enrollment progress — the tape breaks the coil upward toward the FDMC $100/share target and the strategic-acquirer speculation catches. What breaks the setup is a specific efficacy or safety miss on the orka-001 readout; that's when a stock at 76% of the 52-week range gives back to 200-day support 61% below spot as the Fairmount-soaks-capital thesis validates.

Agrees with X sentimentThe bullish X take — Q2 update highlights of $1.1B in cash (fully funded through BLA filing), FDMC ~$7.7B at $100/share, orka-001 Phase 1 28-week data due late Q3 2026 (with 52-week data in December), and orka-001 Phase 2b fully enrolled early with 187 subjects, ORKA grouped with REPL, IMNM, and PTGX as biotech names making new highs — captures the coiled catalyst-play setup exactly; the Fairmount 'soaking capital across ORKA and SYRE' framing is the honest counter.

What to watch: The late-Q3 orka-001 Phase 1 28-week data — positive efficacy plus continued Phase 2b enrollment breaks the coil upward toward the FDMC $100/share target; a specific efficacy or safety miss is what gives back to the 200-day support 61% below spot.

On the calendar: 2026-11-11 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-17

Oruka Therapeutics chatter is bullish - Q2 update highlights include $1.1B in cash (fully funded through BLA filing), FDMC ~$7.7B at $100/share, orka-001 Phase 1 28-week data due late Q3 2026 (with 52-week data in December), and orka-001 Phase 2b fully enrolled early with 187 subjects. ORKA is grouped with REPL, IMNM, and PTGX as biotech names making new highs. One critic frames Fairmount as soaking capital across ORKA and SYRE.

Read the AI verdict + X sentiment for $ORKA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing long-acting monoclonal antibodies (ORKA-001/002) for psoriasis and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ORKA.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ORKA

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-34.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-27.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-0.55$-0.51-7.3%
Q1 2026May 13, 2026$-0.48$-0.55+12.2%
Q4 2025Mar 12, 2026$-0.45$-0.61+26.2%
Q3 2025Nov 12, 2025$-0.55$-0.56+1.8%
Next earningsWed, Nov 11·consensus EPS $-0.58

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.58$-23.7M
Q4 FY25$0———$-0.54$-22.7M
Q3 FY25$0———$-0.69$-21.7M
Q2 FY25$0———$-0.58$-23.2M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.11-$2.41 – -$1.920
FY27$0$0 – $0-$2.51-$2.98 – -$2.310
FY28$0$0 – $0-$3.28-$5.73 – -$1.840
FY29$0$0 – $0-$4.28-$4.28 – -$4.280
FY30$75.6M$75.6M – $75.6M-$4.78-$4.78 – -$4.783

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.77%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+62.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 50.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.395-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 17Joana GoncalvesChief Medical Officer7.0K sh$783KSellAug 14Paul T QuinlanGeneral Counsel52.0K sh$5.6MSellAug 13Arjun AgarwalPresident10.0K sh$1.1MSellJul 15Joana GoncalvesChief Medical Officer7.0K sh$604KSellJul 13Arjun AgarwalPresident10.0K sh$846KSellJul 1Sandler Laura LeeCOO5.0K sh$472KSellJul 1Fairmount Funds Management LlcDirector3.6M sh$300.0MSellJun 22Arjun AgarwalPresident1.6K sh$128KSellJun 15Arjun AgarwalPresident395 sh$28KSellJun 15Joana GoncalvesChief Medical Officer7.9K sh$551K
1–10 of 20
+ 14 other (12 exempts · 1 award · 1 conversion) in window

See when $ORKA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 28424B5
AI summary

Oruka Therapeutics (ORKA) filed a 424B5 prospectus supplement to offer and sell up to $500 million in common stock through an at-the-money (ATM) equity distribution program, with TD Cowen acting as sales agent under a Sales Agreement amended August 21, 2026. The ATM structure allows Oruka to sell shares incrementally into the market at prevailing prices, minimizing dilution impact compared to a traditional block offering. Proceeds are intended for general corporate purposes, which for a clinical-stage biotech typically means funding ongoing trials and operations. This is a capital runway extension tool rather than a discrete capital raise event.

3New insider — initial holdingsAug 253
AI summary

Oruka Therapeutics, Inc. (ORKA) filed a Form 3 initial beneficial ownership statement for Larry Todd Edwards, Chief Commercial Officer, as of August 24, 2026, at 855 Oak Grove Ave., Suite 100, Menlo Park, CA. The filing establishes Edwards's initial equity ownership baseline as a new Section 16 reporting officer. This is a routine administrative filing for a new executive officer at the dermatology-focused clinical-stage biotech.

8-KOfficer or director changeAug 248-K — Item 5.02: Officer or director change
AI summary

Oruka Therapeutics, Inc. (ORKA, Menlo Park CA), a clinical-stage biotech developing biologic treatments for chronic skin diseases, filed a current report on August 24, 2026 disclosing a change in executive officers or directors (Item 5.02) with exhibits. This is a companion to the concurrent Form 3 (Larry Edwards, CCO) filed on the same date, suggesting a new executive appointment. Leadership changes at clinical-stage biotechs are material for tracking management teams.

S-3Shelf registrationAug 21S-3
AI summary

Oruka Therapeutics, Inc. (ORKA, Menlo Park CA), a clinical-stage biotech developing biologics for chronic skin diseases, filed a shelf registration statement (Form S-3) on August 21, 2026, with General Counsel Paul Quinlan as contact and counsel Davis Polk & Wardwell LLP (Alan Denenberg, Elizabeth LeBow, Redwood City CA). The S-3 authorizes future securities offerings; specific scope is in the full document. This shelf filing accompanies the concurrent Form 3 (Larry Edwards, CCO) and 8-K (5.02 leadership change), suggesting active capital markets positioning for clinical development.

SC 13D/AActivist amendmentJul 1SC 13D/A
AI summary

Fairmount Funds Management LLC filed an amended Schedule 13D for ORKA (CUSIP 687604108), disclosing shared voting and dispositive power over 14,553,895 shares with zero sole power. Amendment to a previously disclosed 5%+ passive position.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary

Delaware 000-22873 36-3855489 disclosed voting results from its annual or special meeting. f Matters to a Vote of Security Holders. On June 2, 2026, Oruka Therapeutics, Inc. (the “ Company ”) held its Annual Meeting of Stockholders (the “ Annual Meeting ”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-vote...

SC 13D/AActivist amendmentMay 4SC 13D/A
AI summary

Amendment No. 5 to Schedule 13D filed by Fairmount Funds Management LLC reporting beneficial ownership of ORUKA THERAPEUTICS, INC. representing a 9% stake (0 shares), with investment intent. This SC 13D/A filing dated 2026-05-04 updates the holder's position and disclosed intentions.

424B5Prospectus supplement (offering)Apr 29424B5
AI summary

ORKA filed a 424B5 prospectus supplement on 2026-04-29 of 9,660,000 Shares at $0.001 per share. This represents dilution happening now.

+ 24 other (6 13Gs · 2 EFFECTs · 2 10-Qs · 2 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Knowzacks.com·4d agoBlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKAdefenseworld.net·7d agoOruka Therapeutics Appoints Todd Edwards as Chief Commercial Officerglobenewswire.com·8d ago4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026zacks.com·21d agoOruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·22d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport